Skip to content

Find our latest news, stories and insights

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

Catch up on the latest press releases and download media assets here

  1. Home/
  2. News/
  3. Innovation/
  4. Award criteria
speaker

Award criteria

About the award:

The Scholars Award is a three-year award in the gross amount of $150,000, which will be paid to the University (the “Recipient”) for the benefit of the Johnson & Johnson Scholar and her research, with the understanding that the Recipient will administer the funds. The Scholars Award will be paid in three (3) installments of U.S. $50,000 per year of the three-year scholarship period, payable in 2022, subject to compliance with the terms and conditions of the program’s Agreement. Winners achievements will also be showcased at a symposium.

The following award criteria applies:

Standards for evaluation:

Judges will use the following criteria to evaluate the applications:

  • Scientific/technical expertise exhibited
  • Novelty/innovation of the research
  • Potential impact of the research
  • Feasibility of the research

You must be a woman working in the field(s) of Science, Technology, Engineering, Mathematics, Manufacturing and Design (STEM2D).

You must be an early to mid-career women working within a STEM2D university department at the time of application at an accredited academic university, institution or design school. Examples include a non-tenured assistant professor, assistant professor or associate professor.

The female scholar should have a minimum degree for the appropriate field:

  • Science; M.D., Ph.D.
  • Technology; Ph.D.
  • Engineering; Ph.D.
  • Math; M.S., Ph.D.
  • Manufacturing; Ph.D.
  • Design; M.A., M.S., MDes, MArch, MFA, MLA, Ph.D.

WiSTEM2D Scholars Award

The Johnson & Johnson WiSTEM²D Scholars Award Program will help develop female leaders and support innovation in STEM fields.

More from Johnson & Johnson

Moving toward a more personalized approach to treating depression

The World Health Organization predicts that depression will be the leading cause of disability across the globe by 2030. Learn how Johnson & Johnson is on a mission to change that.

“Our goal is a solution for every bladder cancer patient”

Meet Christopher Cutie, M.D., the Johnson & Johnson scientist who’s helping change the treatment landscape for people with bladder cancer, the tenth most common cancer in the world.

Is this the end of one-size-fits-all treatments for depression?

Learn how Johnson & Johnson is working to better address the needs of the 7 in 10 people with depression whose treatments aren’t providing enough relief.